Comparison of baseline characteristics according to clinical outcome
| Poor Outcome (mRS > 2) (n = 60) | Good Outcome (mRS ≤ 2) (n = 44) | P Value | |
|---|---|---|---|
| Age (yr) | 74 (65–81) | 66 (58–76) | .005 |
| Male (No.) (%) | 33 (55.0%) | 28 (63.6%) | .424 |
| Baseline NIHSS (mean) | 16 ± 5 | 11 ± 6 | <.001 |
| Onset-to-needle time (mean) (min) | 230 (168–297) | 207 (119–259) | .059 |
| Endovascular thrombectomy (No.) (%) | 22 (36.7%) | 16 (36.4%) | 1.000 |
| Prior antiplatelet usage (No.) (%) | 12 (20.0%) | 9 (20.5%) | 1.000 |
| Risk factors | |||
| Smoking (No.) (%) | 18 (30.0%) | 13 (29.5%) | 1.000 |
| Hypertension (No.) (%) | 35 (58.3%) | 22 (50.0%) | .431 |
| Diabetes mellitus (No.) (%) | 16 (26.7%) | 6 (13.6%) | .146 |
| Hyperlipidemia (No.) (%) | 22 (36.7%) | 21 (47.7%) | .315 |
| History of stroke/TIA (No.) (%) | 11 (18.3%) | 5 (11.4%) | .415 |
| Atrial fibrillation (No.) (%) | 38 (63.3%) | 20 (45.5%) | .076 |
| Radiologic data | |||
| Baseline infarct core volume (mean) (mL) | 69.27 ± 49.51 | 40.72 ± 30.91 | .001 |
| Baseline hypoperfusion volume (mean) (mL) | 134.28 ± 61.07 | 98.22 ± 60.43 | .004 |
| TAImax (median) (IQR) (HU) | 18.0 (10.0–38.7) | 39.9 (26.1–73.3) | <.001 |
| TAIpeak (median) (IQR) (HU) | 4.6 (−4.2–17.5) | 18.7 (5.9–43.0) | <.001 |
| TAIcon (median) (IQR) (HU) | 2.2 (−5.5–12.4) | 10.4 (−2.0–36.7) | .006 |
| Thrombus perviousness by dichotomized TAImax (No.) (%) | 18 (30.0%) | 31 (70.5%) | <.001 |
| Thrombus perviousness by dichotomized TAIpeak (No.) (%) | 22 (36.7%) | 31 (70.5%) | .001 |
| Thrombus perviousness by dichotomized TAIcon (No.) (%) | 13 (21.7%) | 21 (47.7%) | .005 |